The history of H1 antagonists began around 1937, due to side effects as sedation, this treatment was not such frequently recommended. Recently developed antihistaminics presents good clinical efficacy and  less side antihistaminics, specially the second generation, are commonly used for varies spectrum of allergic disease. There is an increasing evidence that newly developed antihistamines presents both anti-inflammatory and anti-allergic action. The inhibition of the release of mediators and cytokines (histamine, triptase, LTC4, PGD2, IL-6, IL-8, IL-3, GM-CSF, TNF-α) from mast cells and basophiles were found, as well as decreased concentration of  ICAM- 1, RANTES, IL-8 after allergen- challenge. Antihistamines inhibits early and late phase of allergic reaction in seasonal allergic rhinitis. There are promising data from studies concerning the efficacy of rupatadine and norpiperidine, newly developed selective antihistamines.  

This is an important consideration of the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative which provides a scientific basis for defining what are the desirable properties of an potentially most effective antihistamines.  The recommendations presented in the manuscript are based on ARIA, Global Initiative for Asthma (GINA) and current publications. Varies spectrum of antihistaminics are used in allergic diseases – as general, topical treatment, as well in combinations.